Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals
Executive Summary
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
You may also be interested in...
Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.
Horizon And Arrowhead To Develop RNAi Therapeutic For Gout
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.
With Return Of Tepezza Supply, Horizon Is Ready To Get Back To Business
US FDA approved new manufacturing for Tepezza, which had been sidelined by COVID-19 vaccine production. Horizon said it will resupply the market in April.